Brief: Freeline Presents Positive New Data From Phase 1/2 GALILEO-1 Trial Of FLT201

Freeline Therapeutics Holdings

25/10/2023 07:04

Oct 25 (Reuters) - Freeline Therapeutics Holdings Plc
 FRLN.O :
    * FREELINE PRESENTS POSITIVE NEW DATA FROM PHASE 1/2
GALILEO-1
TRIAL OF FLT201, ITS NOVEL GENE THERAPY CANDIDATE, IN GAUCHER
DISEASE AT ESGCT 30TH ANNUAL CONGRESS
    * FLT201 CONTINUES TO BE WELL-TOLERATED, WITH NO SERIOUS
ADVERSE
EVENTS

Source text for Eikon:  ID:nGNXbFbhp3 
Further company coverage:  FRLN.O 

 ((Reuters.Briefs@thomsonreuters.com;))